Fourth-generation HIV screening test combining antibody detection (HIV-1 and HIV-2) with P24 antigen detection. P24 capsid antigen appears 10-14 days after exposure, before antibody formation, enabling earlier detection of acute HIV infection. Test includes reflex confirmatory testing for reactive results.

Urine culture and antimicrobial sensitivity testing. Identifies bacterial, fungal, or yeast pathogens causing UTI. Quantifies colony-forming units (CFU/mL) – significant bacteriuria defined as ≥100,000 CFU/mL for clean-catch midstream urine. Common organisms tested include E. coli, Klebsiella, Proteus, Enterococcus, Staphylococcus saprophyticus, Pseudomonas, Candida species. Includes antibiotic susceptibility panel showing sensitive, intermediate, and resistant classifications for relevant antimicrobial agents to guide treatment selection.

Cervical cytology examination using spatula and cytobrush to collect cells from ectocervix and endocervical canal. Microscopic analysis of cervical epithelial cells to detect dysplasia, koilocytosis (HPV-related changes), atypical squamous cells (ASC-US, ASC-H), squamous intraepithelial lesions (LSIL, HSIL), atypical glandular cells (AGC), or malignant cells. Reported using Bethesda System classification. Screening for cervical precancerous and cancerous changes.

Microbiological culture of urine specimen on selective media (blood agar, MacConkey agar, CLED agar). Bacterial identification using biochemical tests or MALDI-TOF mass spectrometry. Colony count quantification reported as CFU/mL (colony-forming units per milliliter). Significant growth typically ≥100,000 CFU/mL for single organism. Includes comprehensive antibiotic sensitivity testing (disk diffusion or automated MIC determination) reporting susceptibility profile for beta-lactams, fluoroquinolones, aminoglycosides, trimethoprim-sulfamethoxazole, nitrofurantoin, and other relevant antibiotics. Results guide targeted antimicrobial therapy.

Quantitative measurement of total prostate-specific antigen (PSA) in serum. PSA is a glycoprotein enzyme produced primarily by prostate epithelial cells. Measured in nanograms per milliliter (ng/mL). Elevated levels may indicate prostate conditions including benign prostatic hyperplasia (BPH), prostatitis, or prostate cancer. Age-specific reference ranges typically: <40 years: 0-2.0 ng/mL, 40-49 years: 0-2.5 ng/mL, 50-59 years: 0-3.5 ng/mL, 60-69 years: 0-4.5 ng/mL, 70+ years: 0-6.5 ng/mL.

Comprehensive semen analysis examining: volume (normal ≥1.5 mL), pH (normal 7.2-8.0), liquefaction time (normal ≤60 minutes), sperm concentration (normal ≥15 million/mL), total sperm count (normal ≥39 million per ejaculate), motility categories (progressive, non-progressive, immotile; normal total motility ≥40%, progressive motility ≥32%), morphology using strict Kruger criteria (normal forms ≥4%), vitality (normal ≥58% live), white blood cell count (normal <1 million/mL), presence of agglutination, and viscosity. Analysis performed according to WHO 2021 guidelines for male fertility assessment.

Type-specific antibody testing for Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). Separate detection of IgG antibodies (indicating past or chronic infection) and IgM antibodies (indicating recent or active infection) for each virus type. Serological differentiation between oral herpes (typically HSV-1) and genital herpes (typically HSV-2).

PCR detection of Neisseria gonorrhoeae DNA in urogenital, rectal, or pharyngeal samples. Identifies active bacterial infection causing gonorrhea. Highly sensitive nucleic acid amplification test (NAAT) with specimen-specific detection.

PCR (polymerase chain reaction) detection of Chlamydia trachomatis DNA in urogenital samples. Identifies active bacterial infection of the urogenital tract, cervix, urethra, or rectum. Detects bacterial genetic material with high sensitivity and specificity.

Rapid immunoassay for HIV 1 and HIV 2 antibody detection using finger-stick blood sample. Results available within 15-20 minutes. Detects antibodies produced 3-12 weeks after exposure. Reactive results require confirmatory testing with laboratory-based HIV antibody/antigen assay.

PCR detection and genotyping of 30 HPV strains including high-risk oncogenic types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) associated with cervical cancer, and low-risk types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, CP6108) associated with genital warts. Identifies specific viral genotypes present in cervical, vaginal, penile, or anal samples.

Comprehensive PCR detection of 49 HPV genotypes including all 14 high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), probable high-risk types (26, 53, 67, 68, 70, 73, 82), and low-risk types (6, 11, 40, 42, 43, 44, 54, 61, 62, 71, 72, 81, 83, 84, 87, 89, 90, 91, CP6108, and others). Provides complete HPV strain identification with risk stratification for clinical management.

VDRL (Venereal Disease Research Laboratory) flocculation test for syphilis screening. Non-treponemal antibody test detecting IgM and IgG reagin antibodies produced in response to cellular damage caused by Treponema pallidum infection. Results reported as non-reactive, weakly reactive, or reactive with titer quantification (e.g., 1:2, 1:4, 1:8, 1:16, etc.). Reactive results require confirmatory treponemal testing (TPHA, FTA-ABS, or TP-PA). Used for screening and monitoring treatment response.

Includes: Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium, Trichomonas vaginalis. Focused panel for the four most common treatable sexually transmitted bacterial and parasitic infections.

Includes: Chlamydia trachomatis, Herpes simplex virus type I, Herpes simplex virus type II, Mycoplasma genitalium, Mycoplasma hominis, Neisseria gonorrhoeae, Ureaplasma parvum, Ureaplasma urealyticum. Testing performed using PCR (polymerase chain reaction) methodology for accurate detection.

Includes: Chlamydia trachomatis, Gardnerella vaginalis, Herpes simplex virus I, Herpes simplex virus II, Mycoplasma genitalium, Mycoplasma hominis, Neisseria gonorrhoeae, Ureaplasma urealyticum, Trichomonas vaginalis, Treponema pallidum (syphilis), Ureaplasma parvum, Haemophilus ducreyi (chancroid).

Includes: All pathogens from the 13 Pathogen Panel plus: Candida albicans, Candida glabrata, Candida krusei, Candida parapsilosis, Candida tropicalis. This extended panel screens for both bacterial and fungal sexually transmitted infections.

Includes: All pathogens from the 17 Pathogen Panel plus: Hepatitis B surface antigen (HBsAg), Hepatitis C antibody, Syphilis RPR (rapid plasma reagin), HIV 1 & 2 combination antibody/antigen test, HIV P24 antigen (early detection marker). Comprehensive screening for viral, bacterial, and fungal STIs.

Includes: HIV 1&2 antibodies, HIV P24 antigen (early detection), Hepatitis A antibody, Hepatitis B surface antigen, Hepatitis C antibody, Gardnerella vaginalis, Candida species (albicans, glabrata, krusei, parapsilosis, tropicalis), Ureaplasma parvum, Ureaplasma urealyticum, Chlamydia trachomatis, Trichomonas vaginalis, Haemophilus ducreyi, Herpes simplex I & II, Mycoplasma hominis, Mycoplasma genitalium, Neisseria gonorrhoeae, Treponema pallidum, TPHA (Treponema pallidum hemagglutination), Syphilis VDRL, RPR (rapid plasma reagin).

Includes: Candida species (albicans, glabrata, krusei, parapsilosis, tropicalis, dubliniensis, lusitaniae), Mycoplasma genitalium, Mycoplasma hominis, Neisseria gonorrhoeae, Trichomonas vaginalis, Cytomegalovirus (CMV), Atopobium vaginae, Haemophilus ducreyi, Bacterial vaginosis-associated bacterium 2 (BVAB2), Bacteroides fragilis, Varicella-zoster virus (VZV), Megasphaera type 1, Treponema pallidum, Chlamydia trachomatis, Gardnerella vaginalis, Herpes simplex I & II, Ureaplasma parvum, Ureaplasma urealyticum, Lymphogranuloma venereum (LGV), Lactobacillus species, Mobiluncus species.

Includes: HIV 1&2 + P24 antigen, Syphilis (Treponema pallidum, TPHA), Hepatitis B surface antigen, Hepatitis C antibody, Candida species (albicans, glabrata, krusei, parapsilosis, tropicalis, dubliniensis, lusitaniae), Mycoplasma genitalium, Mycoplasma hominis, Neisseria gonorrhoeae, Trichomonas vaginalis, Cytomegalovirus (CMV), Atopobium vaginae (2 strains), Haemophilus ducreyi, Bacteroides fragilis, Bacterial vaginosis-associated bacterium 2 (BVAB2), Chlamydia trachomatis, Gardnerella vaginalis, Herpes simplex I & II, Ureaplasma parvum, Ureaplasma urealyticum, Lymphogranuloma venereum, Lactobacillus species, Mobiluncus species, Megasphaera type 1, Varicella-zoster virus (VZV).

Includes: All pathogens from GC Ultimate 36 Pathogen Panel plus High-risk HPV screening covering 30 human papillomavirus genotypes associated with increased risk of cervical, anal, and oropharyngeal cancers.

Includes: All pathogens from GC Ultimate 36 Pathogen Panel, High-risk HPV panel (49 genotypes), and Low-risk HPV panel (10 genotypes). This is the most comprehensive STI screening available, covering viral, bacterial, fungal, and parasitic infections including cancer-associated HPV strains.